Találati lista | Tudóstér

001-es BibID:	BIBFORM093765
035-os BibID:	(WoS)000512990500007 (Scopus)85078431398
Első szerző:	Chichareon, Ply
Cím:	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention : pre-specified subgroup analysis from the randomized GLOBAL LEADERS study / Ply Chichareon, Rodrigo Modolo, Norihiro Kogame, Kuniaki Takahashi, Chun-Chin Chang, Mariusz Tomaniak, Roberto Botelho, Eric Eeckhout, Sjoerd Hofma, Diana Trendafilova-Lazarova, Zsolt Kőszegi, Andres Iñiguez, Joanna J. Wykrzykowska, Jan J. Piek, Scot Garg, Christian Hamm, Philippe Gabriel Steg, Peter Jüni, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys
Dátum:	2020
ISSN:	0021-9150
Megjegyzések:	Background and aims: Diabetes has been well recognized as a strong predictor for adverse outcomes after percutaneous coronary intervention (PCI), however, studies in the era of drug-eluting stent and potent P2Y12 inhibitors have shown conflicting results. We aimed to assess ischemic and bleeding outcomes after contemporary PCI according to diabetic status. Methods: We studied 15,957 patients undergoing PCI for stable or acute coronary syndrome in the GLOBAL LEADERS study with known baseline diabetic status. The primary endpoint was all-cause death or new Q-wave myocardial infarction at 2 years. The secondary safety endpoint was major bleeding defined as bleeding academic research consortium (BARC) type 3 or 5. Results: A quarter of the study cohort were diabetic (4038/15,957), and these patients had a significantly higher risk of primary endpoint at 2 years compared to non-diabetics (adjusted hazard ratio [HR] 1.38; 95% confidence interval [CI] 1.17-1.63). The difference was driven by a significantly higher risk of all-cause mortality at 2 years in diabetics (adjusted HR 1.47, 95% CI 1.22-1.78). The risk of BARC 3 or 5 bleeding was comparable between the two groups (adjusted HR 1.09, 95% CI 0.86-1.39). The antiplatelet strategy (experimental versus reference strategy) had no significant effect on the rates of primary endpoint and secondary safety endpoint at 2 years in patients with and without diabetes. Conclusions: Diabetic patients had higher risk of ischemic events after PCI than non-diabetic patients, whilst bleeding risk was comparable. The outcomes of diabetic patients following PCI were not affected by the two different antiplatelet strategies.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Coronary artery disease Diabetes Percutaneous coronary intervention Ticagrelor
Megjelenés:	Atherosclerosis. - 295 (2020), p. 45-53. -
További szerzők:	Modolo, Rodrigo Kogame, Norihiro Takahashi, Kuniaki Chang, Chun-Chin Tomaniak, Mariusz Botelho, Roberto Eeckhout, Eric Hofma, Sjoerd Trendafilova-Lazarova, Diana Kőszegi Zsolt (1962-) (kardiológus, belgyógyász) Iñiguez, Andres Wykrzykowska, Joanna J. Piek, Jan J. Garg, Scot Hamm, Christian Steg, Philippe Gabriel Jüni, Peter Vranckx, Pascal Valgimigli, Marco Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: